Trial Information
A Comparison of 2 Schedules of Meloxicam to Reduce Prostate Swelling in Permanent Seed Prostate Brachytherapy - A Randomized Phase III Trial
Inclusion Criteria:
- Eligible to receive prostate brachytherapy as per the Ontario Provincial Guidelines
will be eligible for this study (i.e. prostate specific antigen [PSA] < 10, Gleason
score <7, Stage <= T2a)
Exclusion Criteria:
- Patients already taking anti-inflammatory drugs
- Patients with allergic-type reactions, including asthma and urticaria, to aspirin or
nonsteroidal anti-inflammatory agents (see product information)
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
To compare 2 schedules of MeloxicamTM given in the peri-operative period to reduce prostate swelling after permanent seed implantation for prostate cancer
Principal Investigator
Juanita Crook, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Princess Margaret Hospital, Canada
Authority:
Canada: Ethics Review Committee
Study ID:
UHN REB 03-0840-C
NCT ID:
NCT00152919
Start Date:
February 2004
Completion Date:
May 2009
Related Keywords:
- Prostatic Neoplasms
- Neoplasms
- Prostatic Neoplasms